In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best NASDAQ dividend stocks to buy. The NASDAQ, heavily comprised of technology ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the development and commercialization of innovative therapies for diseases such ...

Gilead will pay LEO Pharma $250 million upfront under the arrangement; further milestone payments may boost the total to $1.7 billion. While LEO Pharma maintains worldwide rights to topical ...

All of this may suggest that Gilead is fairly valued at present, although there may be a case to be argued that the recent momentum can be built upon in 2025, making this a good time to buy shares.

In this article, we are going to take a look at where Gilead Sciences ... innovation remains strong, and there is a better investment environment for biotech. Lower interest rates have also ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (SNSE:GILDCL) from Equal-Weight to Overweight. There are 2,888 funds or institutions reporting ...